Funding Announcements

"With the support of our investors, we are on the cusp of revolutionising brain aneurysm treatment. Our team is dedicated to working with regulators, medical professionals, and industry experts to bring this product to market and address a condition impacting countless individuals worldwide."

"Essentially, our technology generates very small droplets which are ideal for peripheral inhalation drug delivery, and also the potential for systemic drug delivery through the inhalation route rather than via injection."

"CAD is a leading cause of death worldwide and represents an area with significant unmet medical need. The continued support from our existing investors and additional funding from the Future Fund reinforces the potential of our technology and BIOCARTA database, and brings us closer to achieving our vision of opening a new frontier of precision medicine for millions of patients with CAD worldwide."

"We are seeing pivotal growth across our industry, whereby drug developers are increasingly recognising the potential of OOC technology to augment, supplement and optimize their workflows."

"The close of our Series A round marks the 'end of the beginning' and the start of a new chapter for Qureight, as we turn our focus to developing our platform and creating products in new disease areas. Our mission to extend the lives of lung and heart disease patients will be bolstered by the invaluable expertise of our new board and new senior team members, and we are looking forward to adding to our strategic biopharma collaborations."